Information: Detta är inte den senaste versionen av datamodellen. Du hittar en versionsöversikt till vänster under versioner. Den senaste versionen hittar du här.
Information:
Fel:
ID
34386
Beskrivning
Gadoxetic Acid-enhanced MR Evaluation of Hepatocellular Carcinoma and Dysplastic Nodules in the Cirrhotic Liver; ODM derived from: https://clinicaltrials.gov/show/NCT01501240
Länk
https://clinicaltrials.gov/show/NCT01501240
Nyckelord
Versioner (2)
- 2019-01-17 2019-01-17 -
- 2019-05-14 2019-05-14 -
Rättsinnehavare
see on clinicaltrials.gov
Uppladdad den
17 januari 2019
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Liver Cirrhosis NCT01501240
Eligibility Liver Cirrhosis NCT01501240
- StudyEvent: Eligibility
Similar models
Eligibility Liver Cirrhosis NCT01501240
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
ID.1
Item
patients with known liver cirrhosis based on either histology, or a combination of physical examination, laboratory tests, and imaging data
boolean
ID.2
Item
patients with known liver cirrhosis based on either histology, or a combination of physical examination, laboratory tests, and imaging data
boolean
ID.3
Item
patients under 20 years of age
boolean
ID.4
Item
patients who have more than 10 nodules detected on hepatobiliary phase of gadoxetic acid-enhanced mr
boolean
ID.5
Item
patients who underwent transarterial chemotherapy or radiofrequency ablation
boolean
ID.6
Item
women who are pregnant, lactating or who are of childbearing potential
boolean
ID.7
Item
patients with any physical or mental status than interferes with the signing of informed consent
boolean
ID.8
Item
patients with a contraindication for mr
boolean
ID.9
Item
patients with impaired renal function (e.g. acute renal failure or egfr < 30 ml/min/1.73m2) or patients on dialysis
boolean